| 李 擎,刘 勇,于 洋.阿帕替尼在晚期肺鳞癌治疗中的临床应用[J].肿瘤学杂志,2018,24(9):888-891. |
| 阿帕替尼在晚期肺鳞癌治疗中的临床应用 |
| Preliminary Clinical Application of Apatinib in Treatment of Advanced Lung Squamous Cell Carcinoma |
| 投稿时间：2017-07-24 |
| DOI：10.11735/j.issn.1671-170X.2018.09.B009 |
|
 |
| 中文关键词: 肺癌 鳞状细胞癌 阿帕替尼 |
| 英文关键词:lung cancer squamous cell carcinoma apatinib |
| 基金项目: |
|
| 摘要点击次数: 2392 |
| 全文下载次数: 366 |
| 中文摘要: |
| 摘 要：［目的］ 初探阿帕替尼用于晚期肺鳞癌的疗效及安全性。［方法］ 回顾性分析阿帕替尼单药或联合化疗的晚期肺鳞癌10例患者（Ⅲb期~Ⅳ期）的近期疗效、毒副反应、无进展生存时间及总生存时间。［结果］ 共纳入10例可评估的患者，3例部分缓解（30%），病情稳定5例（50%），疾病控制率为80.0%。中位 PFS和中位OS分别为4.6个月和13.4个月。阿帕替尼相关的毒性3度不良反应为手足综合征1例，恶心呕吐1例，中性粒减少1例，其余均为1~2度不良反应。［结论］ 阿帕替尼治疗晚期肺鳞癌可取得较好的客观疗效并且安全性良好。 |
| 英文摘要: |
| Abstract：［Objective］ To evaluate the efficacy and safety of apatinib in treating advanced lung squamous cell carcinoma(SCC). ［Methods］ We retrospectively analyzed the short-term efficacy and toxicity of apatinib monotherapy or combing with traditional chemotherapy in treating advanced lung squamous cell carcinoma patients(stage Ⅲb~Ⅳ). ［Results］ Ten patients were included in the present study，3 patients achieved partial response，and 5 achieved stable disease，which represented an objective response rate (ORR) of 30% and a disease control rate (DCR) of 80%. Median progression-free survival and overall survival were 4.6 months and 13.4 months respectively. The toxicity of apatinib related was generally tolerated. ［Conclusion］ Apatinib appears to be effective and safe for advanced squamous cell lung cancer. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|